Table 1. NS5A L31/Y93 RASs at baseline and after failure in patients treated with ASV/DCV.
| Case | Baseline (A) |
Result | After failure (B) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| L31-Y93 | L31M/V-Y93 | L31-Y93H | L31M/V-Y93H | L31-Y93 | L31M/V-Y93 | L31-Y93H | L31M/V-Y93H | ||
| 1 | 2.3% | M 57.0% | H 0.8% | M-H 38.9%* | relapse | — | — | — | M-H 99.0% |
| 2 | 25.9% | V 3.2% | H 57.6% | V-H 12.9%* | relapse | — | — | — | V-H 98.2% |
| 3 | 97.6% | M 0.4% | H 0.3% | M-H 0.1%* | breakthrough | — | — | H 0.7% | M-H 97.5% |
| 4 | — | — | H 99.2% | V-H 0.1%* | relapse | — | — | — | V-H 99.4% |
| 5 | — | — | H 96.2%* | V-H 0.3% | breakthrough | — | — | — | V-H 97.7% |
| 6 | 39.1% | — | H 59.8%* | M-H 0.3% | relapse | 1.5% | — | H 0.7% | M-H 97.0% |
| 7 | 94.6% | — | H 3.0%* | — | breakthrough | — | — | — | V-H 93.0% |
| 8 | 98.6%* | M 0.7% | — | — | relapse | — | — | — | V-H 53.7% |
| M-H 43.9% | |||||||||
| 9 | 98.8% | — | — | — | relapse | — | — | — | M-H 93.8% |
| 10 | 97.9% | — | — | — | relapse | — | — | H 0.6% | M-H 98.2% |
| 11 | 99.0% | — | — | M-H 0.2% | breakthrough | 99.5% | — | — | — |
*Represents the putative original variants before treatment that contributed to the L31M/V-Y93H double substitution after treatment.